tiprankstipranks
Trending News
More News >
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
US Market
Advertisement

TransCode Therapeutics (RNAZ) AI Stock Analysis

Compare
426 Followers

Top Page

RNAZ

TransCode Therapeutics

(NASDAQ:RNAZ)

Rating:27Underperform
Price Target:
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
Positive Factors
Clinical Progress
The safety review committee has approved opening of Cohort 4 in the Phase 1 trial evaluating TTX-MC138 in advanced/metastatic solid tumors, based on favorable safety observed in previous cohorts.
Drug Effectiveness
The company observed a miRNA-10b inhibition of ~66% in Cohort 1, indicating the drug's effectiveness even at low doses in the blood.
Strategic Growth
The company is engaged in potential pipeline partnerships, indicating strategic growth opportunities following the presentation of initial data.
Negative Factors
Financial Performance
In 4Q24, the company reported operating expenses of $5.1M, which was significantly higher than 3Q24, likely associated with costs related to dose escalation in the Phase 1 trial of TTX-MC138 for treatment of solid tumors.
Funding Risks
Risks include, but are not limited to: safety signals emerge with any of the company’s clinical or preclinical programs; efficacy from clinical programs is lower than expected or the company’s studies do not achieve statistical significance.

TransCode Therapeutics (RNAZ) vs. SPDR S&P 500 ETF (SPY)

TransCode Therapeutics Business Overview & Revenue Model

Company DescriptionTransCode Therapeutics (RNAZ) is a biotechnology company focused on developing RNA-based therapeutics for the treatment of cancer and other diseases. Operating within the pharmaceutical and biotechnology sectors, TransCode leverages its proprietary platform to design and deliver RNA-targeted therapies, aiming to address significant unmet medical needs. The company's core products include a pipeline of therapeutics targeting various forms of cancer, utilizing their expertise in RNA technologies to innovate in precision medicine.
How the Company Makes MoneyTransCode Therapeutics primarily generates revenue through the development and potential commercialization of its RNA-based therapeutic candidates. The company may enter into collaborative agreements or partnerships with larger pharmaceutical companies to co-develop or license its technologies, which can result in upfront payments, milestone payments, and royalties on sales. Additionally, TransCode might receive funding through grants or research collaborations that support their R&D activities. As a biotechnology firm, the company's earnings are heavily reliant on the successful clinical development and eventual market approval of its drug candidates.

TransCode Therapeutics Financial Statement Overview

Summary
TransCode Therapeutics is in the early stages of development with no revenue generation yet. The financials reflect a typical high-risk, high-reward profile of a biotech startup, with significant losses and reliance on external funding. The company must achieve milestones to attract further funding and transition towards revenue generation to improve financial health.
Income Statement
10
Very Negative
TransCode Therapeutics has not generated any revenue over the past years, which is typical for early-stage biotech companies. The company consistently reports net losses, with a significant increase in net loss in the latest year. The lack of revenue and increasing expenses pose a risk to financial sustainability without future funding or revenue streams.
Balance Sheet
20
Very Negative
The company's balance sheet shows negative stockholders' equity, indicating liabilities exceed assets, which is a concern. The debt-to-equity ratio cannot be calculated due to negative equity, and the high liabilities compared to assets reflect financial instability. Cash reserves are present but may not be sufficient to cover ongoing losses.
Cash Flow
15
Very Negative
Operating cash flow is deeply negative, reflecting the company's pre-revenue status and heavy R&D spending. The company has been financing its operations primarily through external financing, as indicated by positive financing cash flows. Free cash flow remains negative, highlighting the need for more sustainable cash generation.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.000.00-98.61K-42.47K0.00
EBITDA-16.19M-17.97M-17.47M-6.11M0.00
Net Income-16.75M-18.55M-35.13M-6.94M-2.74M
Balance Sheet
Total Assets7.29M5.17M7.59M22.94M1.06M
Cash, Cash Equivalents and Short-Term Investments5.81M2.77M4.97M20.83M828.02K
Total Debt38.29K450.57K0.000.002.09M
Total Liabilities9.31M3.53M4.35M2.53M4.46M
Stockholders Equity-2.02M1.64M3.24M20.40M-3.41M
Cash Flow
Free Cash Flow-13.36M-18.11M-15.86M-5.52M-492.97K
Operating Cash Flow-13.34M-18.07M-15.76M-5.27M-492.97K
Investing Cash Flow-21.76K-35.61K-100.92K-251.82K0.00
Financing Cash Flow16.40M15.91M5.99K25.52M1.12M

TransCode Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price11.15
Price Trends
50DMA
8.35
Positive
100DMA
11.81
Negative
200DMA
143.27
Negative
Market Momentum
MACD
0.92
Negative
RSI
56.48
Neutral
STOCH
39.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAZ, the sentiment is Neutral. The current price of 11.15 is above the 20-day moving average (MA) of 9.90, above the 50-day MA of 8.35, and below the 200-day MA of 143.27, indicating a neutral trend. The MACD of 0.92 indicates Negative momentum. The RSI at 56.48 is Neutral, neither overbought nor oversold. The STOCH value of 39.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RNAZ.

TransCode Therapeutics Risk Analysis

TransCode Therapeutics disclosed 91 risk factors in its most recent earnings report. TransCode Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

TransCode Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
46
Neutral
C$202.78M-3.27-23.14%2.83%20.78%-1.17%
42
Neutral
$11.15M-655.00%-26.38%40.99%
38
Underperform
$10.25M
-94.07%52.36%
34
Underperform
$114.09M-590.37%-73095.97%
33
Underperform
$12.43M-339.64%-75.88%
27
Underperform
$9.80M-342.99%99.64%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RNAZ
TransCode Therapeutics
11.15
-244.06
-95.63%
PTNT
Palatin Technologies
0.22
-1.47
-86.98%
EVGN
Evogene
1.18
-3.69
-75.77%
MTVA
MetaVia
0.60
-3.18
-84.13%
SLXN
Silexion Therapeutics
11.32
-1,568.18
-99.28%

TransCode Therapeutics Corporate Events

Delistings and Listing ChangesStock Split
TransCode Therapeutics Announces Reverse Stock Split Approval
Neutral
May 2, 2025

On May 2, 2025, TransCode Therapeutics announced that its stockholders approved a 1-for-28 reverse stock split to meet Nasdaq’s minimum bid price requirements. This move, aimed at increasing the per-share trading price, will reduce the number of outstanding shares from 23,341,336 to approximately 833,620. The reverse stock split will automatically convert twenty-eight current shares into one new share, with no fractional shares issued. The effective date is yet to be determined, and the company will announce it at least two days before implementation. This strategic decision is significant for maintaining the company’s Nasdaq listing and potentially improving its market position.

Spark’s Take on RNAZ Stock

According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.

TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.

To see Spark’s full report on RNAZ stock, click here.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025